CLX Stock Analysis: The Clorox | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 11.882m USD | 12M Return: -11.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 233M
EPS Trend: 38.8%
Qual. Beats: 0
Rev. Trend: -75.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Clorox Company (NYSE: CLX) is a U.S.-based manufacturer and marketer of consumer and professional products sold worldwide, organized into four reportable segments: Health and Wellness, Household, Lifestyle, and International. As a member of the Consumer Staples sector and the Household Products sub-industry, the company sells predominantly non-cyclical, everyday-use goods that tend to generate relatively stable, demand-resilient revenue.
Its brand portfolio spans cleaning and disinfecting products (Clorox, Pine-Sol, Tilex, Liquid-Plumr, Formula 409), professional cleaning solutions (CloroxPro, Clorox Healthcare), bags and wraps (Glad), cat litter (Fresh Step, Scoop Away), grilling (Kingsford), water filtration (Brita), natural personal care (Burts Bees), dressings and sauces (Hidden Valley), and a growing vitamins, minerals, and supplements line (Natural Vitality, RenewLife, NeoCell, Rainbow Light).
Clorox distributes its products through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet, and military stores, third-party and owned e-commerce channels, and distributors, supported by a direct sales force. The company was founded in 1913 and is headquartered in Oakland, California.
- Health and Wellness volumes normalize as pandemic demand fades
- Hidden Valley dressings face pressure from GLP-1 weight loss drugs
- Pricing power tested as private label competition grows in household
| Net Income: 587.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -9.53 > 1.0 |
| NWC/Revenue: -14.12% < 20% (prev -4.38%; Δ -9.74% < -1%) |
| CFO/TA 0.07 > 3% & CFO 576.0m > Net Income 587.0m |
| Net Debt (5.79b) to EBITDA (1.89b): 3.06 < 3 |
| Current Ratio: 0.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (121.8m) vs 12m ago -1.56% < -2% |
| Gross Margin: 42.32% > 18% (prev 45.23%; Δ -2.91% > 0.5%) |
| Asset Turnover: 100.6% > 50% (prev 127.7%; Δ -27.11% > 0%) |
| Interest Coverage Ratio: 12.78 > 6 (EBIT TTM 1.66b / Interest Expense TTM 130.0m) |
| A: -0.12 (Total Current Assets 1.82b - Total Current Liabilities 2.77b) / Total Assets 7.79b |
| B: 0.05 (Retained Earnings 386.0m / Total Assets 7.79b) |
| C: 0.25 (EBIT TTM 1.66b / Avg Total Assets 6.68b) |
| D: 0.01 (Book Value of Equity 90.0m / Total Liabilities 7.54b) |
| Altman-Z'' = 1.05 = BB |
| DSRI: 1.02 (Receivables 791.0m/821.0m, Revenue 6.72b/7.10b) |
| GMI: 1.07 (GM 45.23% / 42.32%) |
| AQI: 1.23 (AQ_t 0.52 / AQ_t-1 0.42) |
| SGI: 0.95 (Revenue 6.72b / 7.10b) |
| TATA: 0.00 (NI 587.0m - CFO 576.0m) / TA 7.79b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of August 05, 2026, the stock is trading at USD 104.67 with a total of 5,240,273 shares traded. Over the past week, the price has changed by +4.34%, over one month by +7.63%, over three months by +21.03% and over the past year by -11.92%.
Current recommended Stop Loss: 97.30 (which is 7% or 2.4 ATR below the current price).
The Clorox has received a consensus analysts rating of 2.89. Therefore, it is recommended to hold CLX.
- StrongBuy: 2
- Buy: 0
- Hold: 13
- Sell: 2
- StrongSell: 2
| Analysts Target Price | 102.4 | -2.2% |
P/E Trailing = 15.9772
P/E Forward = 15.1745
P/S = 1.7577
P/B = 46.5805
P/EG = 2.3693
Revenue TTM = 6.72b USD
EBIT TTM = 1.66b USD
EBITDA TTM = 1.89b USD
Long Term Debt = 2.49b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.17b USD (from shortTermDebt, last quarter)
Debt = 5.93b USD (from shortLongTermDebtTotal, last quarter) + Leases 408.0m
Net Debt = 5.79b USD (calculated: Debt 5.93b - CCE 143.0m)
Enterprise Value = 17.7b USD (11.9b + Debt 5.93b - CCE 143.0m)
Interest Coverage Ratio = 12.78 (Ebit TTM 1.66b / Interest Expense TTM 130.0m)
EV/FCF = 46.49x (Enterprise Value 17.7b / FCF TTM 380.0m)
FCF Yield = 2.15% (FCF TTM 380.0m / Enterprise Value 17.7b)
FCF Margin = 5.65% (FCF TTM 380.0m / Revenue TTM 6.72b)
Net Margin = 8.74% (Net Income TTM 587.0m / Revenue TTM 6.72b)
Gross Margin = 42.32% ((Revenue TTM 6.72b - Cost of Revenue TTM 3.88b) / Revenue TTM)
Gross Margin QoQ = 41.27% (prev 43.23%)
Tobins Q-Ratio = 2.27 (Enterprise Value 17.7b / Total Assets 7.79b)
Interest Expense / Debt = 2.19% (Interest Expense 130.0m / Debt 5.93b)
Taxrate = 25.79% (204.0m / 791.0m)
NOPAT = 1.23b (EBIT 1.66b * (1 - 25.79%))
Current Ratio = 0.66 (Total Current Assets 1.82b / Total Current Liabilities 2.77b)
Debt / Equity = 65.87 (Debt 5.93b / totalStockholderEquity, last quarter 90.0m)
Debt / EBITDA = 3.06 (Net Debt 5.79b / EBITDA 1.89b)
Debt / FCF = 15.22 (Net Debt 5.79b / FCF TTM 380.0m)
Total Stockholder Equity = 49.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.79% (Net Income 587.0m / Total Assets 7.79b)
RoE = 1.20k% (out of range, set to none) (Net Income TTM 587.0m / Total Stockholder Equity 49.0m)
RoCE = 65.54% (EBIT 1.66b / Capital Employed (Equity 49.0m + L.T.Debt 2.49b))
RoIC = 20.38% (NOPAT 1.23b / Invested Capital 6.05b)
WACC = 4.80% (E(11.9b)/V(17.8b) * Re(6.38%) + D(5.93b)/V(17.8b) * Rd(2.19%) * (1-Tc(0.26)))
Discount Rate = 6.38% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.95 | Cagr: -0.88%
[DCF] Terminal Value 73.10% ; FCFF base≈548.4m ; Y1≈480.9m ; Y5≈388.6m
[DCF] Fair Price = 3.74 (EV 6.24b - Net Debt 5.79b = Equity 451.8m / Shares 120.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 38.80 | EPS CAGR: 6.18% | SUE: 0.08 | # QB: 0
Revenue Correlation: -75.91 | Revenue CAGR: -2.84% | SUE: 0.61 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.21 | Chg30d=-4.92% | Revisions=-10% | Analysts=12
EPS next Quarter (2026-12-31): EPS=1.38 | Chg30d=-3.31% | Revisions=-36% | Analysts=12
EPS current Year (2027-06-30): EPS=5.95 | Chg30d=-4.57% | Revisions=-77% | GrowthEPS=+7.7% | GrowthRev=+12.6%
EPS next Year (2028-06-30): EPS=6.45 | Chg30d=-5.00% | Revisions=-44% | GrowthEPS=+8.3% | GrowthRev=+2.6%
[Analyst] Revisions Ratio: -56% (up=6, down=25)